Cubist is testing a new antibacterial in children which has the potential to fight a serious type of diarrhea common to cancer patients called Clostridium difficile more effectively and cheaply than current drugs. The Lexington drug company plans to present results of an early-stage trial this weekend which it says will give early insight into the possibility of using a drug it acquired last year, called Dificid, in kids.